- Healthcare 150
- Posts
- Coverage Gap: 1.4 M Untapped Members for Managed-Care Roll-Ups
Coverage Gap: 1.4 M Untapped Members for Managed-Care Roll-Ups
Millions stranded between Medicaid and ACA subsidies create latent demand—and a prime roll-up arena for managed-care, retail clinic, and insurtech platforms.
Good morning, ! This week we're diving into the Medicaid gap impacting 1.4 million Americans, a $3B pharma megadeal in India, why U.S. healthcare spending is an outlier—and an opportunity, and how patient experience is becoming the defining competitive edge in care delivery.
Join 50+ advertisers who reach our 400,000 executives: Start Here.
Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.
— The Healthcare150 Team
DATA DIVE
The Health Insurance Gap, by the Numbers
Roughly 1.4 million adults fall into the Medicaid coverage gap—earning too much to qualify for Medicaid, but not enough for ACA subsidies. The result? 46.6% of uninsured adults skipped a doctor visit in 2023, often due to cost. The problem is regional (Texas, Florida, Georgia lead the pack), racial (60% of the uninsured are people of color), and structural—80% of the gap includes childless adults, often working but still left out. Mental health? Even worse: two-thirds of insured individuals with a diagnosis still couldn’t access care in 2021. Fixing this isn’t just a moral imperative—it’s an economic one. Depression alone costs the U.S. $44B in lost productivity annually.
TREND OF THE WEEK
The Patient Will See You Now
Healthcare execs are finally catching up to what patients have known for years: experience matters. According to Deloitte, 81% cite patient experience, empowerment, and trust as a top strategic driver for 2025. Yet only 72% are actively prioritizing it. That’s a gap—one that spells opportunity. The old model of transactional care is giving way to consumer-grade service expectations, shaped by Amazon, Apple, and yes, your bank’s app. To win hearts (and reimbursement), providers are doubling down on personalized journeys, digital front doors, and AI-enabled care. In 2025, engagement isn’t a feature—it’s the whole product. (More)
The Private Markets Intelligence Summit of the Year
📍 October 15, 2025 | Well& by Durst, NYC
Join 300+ private markets leaders—GPs, LPs, operating partners, and advisors—for a single day of insights, strategy, and dealmaking at the New York Private Capital Summit.
This isn’t another networking event. It’s where strategy meets substance:
→ Keynotes from HarbourVest’s CEO, Bloomberg, Australian Super
→ Deep-dives on secondaries, direct lending, GenAI, and ESG
→ Practical panels on fund formation, human capital, and tax strategy
→ A spotlight on emerging liquidity tools and NAV-based financing
With over 50 senior speakers from firms like Apollo, KKR, Carlyle, Neuberger Berman, and Warburg Pincus, the Summit is designed for decision-makers driving the next decade of private capital.
Reserve your seat before it sells out: Early Bird Access
MARKET MOVERS
Company (Ticker) | Last Price | 5D |
Eli Lilly and Company (LLY) | $ 778.56 | -1,73% |
Johnson & Johnson (JNJ) | $ 155.75 | 2.27% |
Novo Nordisk A/S (NVO) | $ 69.89 | 3.77% |
Roche Holding AG (ROG.SW) | $ 328.62 | 0.27% |
AbbVie Inc. (ABBV) | $ 191.18 | 3.13% |
HEALTHTECH CORNER
Simplify to Scale
In a high-cost, low-margin environment, pharma leaders are laser-focused on simplification—but not just to cut costs.
According to McKinsey’s Global Life Sciences Leaders Survey, 66% of respondents rank accelerating decision-making as the top simplification priority, followed closely by 62% citing streamlining processes to increase productivity. Surprisingly, traditional cost-cutting ranks fourth, behind reallocating time to higher-value activities.
Why it matters: This marks a pivot from defensive trimming to offensive agility. The simplification agenda is less about lean ops and more about speed, focus, and unlocking organizational capacity. Only 12% cited SKU reduction as a priority—signaling that companies are prioritizing decision velocity and tech-driven enablement over structural pruning.
For healthtech operators and investors, this spells opportunity in platforms that remove friction: workflow orchestration, AI-enabled decision support, and productivity infrastructure. As pharma shifts from “optimize” to “mobilize,” the winners will be the enablers of time, not just cost. (More)
TOGETHER WITH 1440 MEDIA
Seeking impartial news? Meet 1440.
Every day, 3.5 million readers turn to 1440 for their factual news. We sift through 100+ sources to bring you a complete summary of politics, global events, business, and culture, all in a brief 5-minute email. Enjoy an impartial news experience.
DEAL OF THE WEEK
Torrent Bets $3B on Chronic Power + CDMO Scale
Torrent Pharmaceuticals is acquiring a controlling stake in JB Chemicals from KKR in a $3B deal, marking one of India’s largest pharma transactions this year. The deal gives Torrent access to chronic segment brands, a strong Indian franchise, and an entry into ophthalmology. Structure-wise, Torrent will acquire 46.39% upfront, launch a mandatory open offer for 26%, and buy up to 2.8% from JB employees—all at the same per-share price. Post-deal, a merger via share swap is on deck: JB shareholders will get 51 Torrent shares for every 100 held. Regulatory approvals pending, but the synergies? Already in play. (More)
REGIONAL FOCUS
Regional Focus: The U.S. Outlier in Global Health Spending
The U.S. leads the world in healthcare spending—16.5% of GDP. That’s more than 4.5 percentage points above the next highest country, France (11.9%), and nearly 50% higher than the OECD average.
What’s striking isn’t just the top ranking, but the gap. Peer countries like Germany, Japan, and Canada cluster tightly between 11%–12% of GDP. The U.K. and Sweden, often benchmarks for universal coverage, spend just 10.9%.
Why it matters: The U.S. is not getting proportional returns on this investment. Outcomes—such as life expectancy and chronic disease prevalence—lag behind nations spending significantly less. For global investors, this inefficiency signals both risk and opportunity. The American healthcare system is saturated with spending but ripe for disruption.
Expect continued focus on cost-control innovation, value-based models, and digital health tools targeting administrative waste, care navigation, and chronic disease management.
The bottom line: The U.S. isn’t just spending more—it’s spending differently. And the arbitrage is where the upside lies.
"The biggest risk is not taking any risk. In a world that's changing quickly, the only strategy that is guaranteed to fail is not taking risks."
Mark Zuckerberg